Salicylate and mitochondrial monoamine oxidase function in Reye's syndrome.
The main objective of this investigation was to study the effect of salicylate on platelet mitochondrial monoamine oxidase (MAO) activity isolated from blood of two patients with Reye's syndrome. Comparative studies were made with hospitalized children without Reye's syndrome (n = 27) and healthy children (n = 19) serving as controls. Platelet MAO was measured by a radioenzymatic technique with [14C]tyramine as a substrate. The results of this study showed that salicylate (1.0 mM) caused an appreciable inhibition of the platelet MAO activity of patients with Reye's syndrome at the onset of the illness. This was demonstrated by a greater than 50% reduction in enzyme maximum velocity (Vmax) value. The salicylate MAO-inhibitory effect was maintained throughout the duration of the illness. Salicylate had only a minimal MAO-inhibitory effect on platelets isolated from blood of recovered Reye's syndrome patients, healthy controls, and non-Reye's hospitalized children, and no apparent effect on enzyme Vmax values. These preliminary findings suggest that salicylate-induced mitochondrial injury may affect MAO function in children with Reye's syndrome.
D000293:Adolescent; D001792:Blood Platelets / Q000201:enzymology; D002648:Child; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008928:Mitochondria / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects; D012202:Reye Syndrome / Q000139:chemically induced / Q000201:enzymology* / Q000473:pathology; D012459:Salicylates / Q000009:adverse effects*; D020156:Salicylic Acid
D008996:Monoamine Oxidase Inhibitors; D012459:Salicylates; D008995:Monoamine Oxidase; D020156:Salicylic Acid